<DOC>
	<DOCNO>NCT01514344</DOCNO>
	<brief_summary>Phase II , monocentric , open label study assess safety activity intralesional Rituximab treatment indolent CD20+ lymphoma conjunctiva .</brief_summary>
	<brief_title>Intralesional Rituximab Treatment Conjunctival Indolent Lymphoma</brief_title>
	<detailed_description>Preliminary data suggest intralesional rituximab able revert resistance systemic rituximab patient CD20+ indolent lymphoma conjunctiva , addition autologous serum seem exhibit synergistic effect tumor regression . These two main aspect assess trial .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>histological diagnosis CD20+ B cell lymphoma subtypes : marginal zone lymphoma , grade 12 follicular lymphoma , plasmocytic lymphoma , small lymphocyte lymphoma conjunctival localization alone ( 1EA stage ; mono bilateral ) least one measurable lesion age &gt; /= 18 year ECOGPS &lt; /=3 HIV 12 negativity least one previous treatment ( antibiotic rituximab ) concomitant conventional ( chemo , radiation , immuno ) , experimental ( antibiotic ) corticosteroid anticancer therapy know allergy rituximab systemic symptom concurrent diagnosis pemphigus postsurgical conjunctival scar</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>OAL</keyword>
	<keyword>MALT</keyword>
	<keyword>conjunctiva</keyword>
	<keyword>indolent</keyword>
	<keyword>CD20+</keyword>
</DOC>